AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01656460 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic radiation Arm 4
Description: Dose Levels Dose per Fraction Total Dose 4 14 Gy 28 Gy
Study NCT04148326 — intervention group
Intervention type: OTHER
Intervention: No Intervention
Description: There is no intervention for this study.
Study NCT03566199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat Nanoparticle Formulation MTX110
Description: Given IT
Study NCT03566199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Convection-Enhanced Delivery (CED)
Description: Undergo CED
Study NCT00556296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRP104
Description: NRP104 30mg capsule once daily in a.m.
Study NCT05404438 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral Appliances
Description: A pre-experimental, single-group pretest-posttest design was performed. At stage one, each participant underwent a 2-day general sleeping test and a 2-day sleeping test with mouth tape. At stage two, participants underwent conventional impressions for TPD and TED appliances and were then randomly assigned to wear the TPD or TED; together for two days of sleeping test with their mouth taped. After a 2-day break (washout), with the same procedure, participants wore the other appliance for another 2-day sleeping test and decided accordingly the optimal appliance that had reduced their ODI scores more. At stage three, participants wore their optimal appliance mouth-taped during sleep for 6 weeks. At the end of the intervention, all participants underwent few days sleeping test for final results.
Study NCT03200990 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: iVAC2L pVAD
Description: To determine the effects of the new PFLVAD PulseCath® iVAC2L on ventricular loading using left ventricular pressure-volume loops, in association with systemic and pulmonary hemodynamic parameters obtained from right and left catheterization. Additionally, assessments of specific load and flow-dependent humoral factors, and cardiac enzymes, will be made during and after the use of mechanical circulatory support.
Study NCT00314327 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: long-acting injectable risperidone
Description: One week of oral risperidone dosage started at 2mg for the first day and then increased to 4mg. If no side effects are noted, participants are started on the long-acting risperidone. The usual dosage of long-acting risperidone in the study will be 25mg every 2 weeks for a total of 12 weeks. The medication will be administered intramuscularly via injection.
Study NCT01422213 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: capsules; daily; orally
Study NCT01422213 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vortioxetine (Lu AA21004)
Description: encapsulated tablets; daily; orally
Study NCT00556296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRP104
Description: NRP104 50mg capsule once daily in a.m.
Study NCT00556296 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NRp104
Description: NRP104 70mg capsule once daily in a.m.
Study NCT00556296 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT02064361 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High intensity exercise
Description: Subjects performed a repeated Wingate protocol for the exercise condition of the study. This consisted of 4, 30 s maximal efforts on a weight-braked cycle ergometer (Monark 894E, Monark Exercise AB, Sweden) with 4 min active recovery between efforts, preceded by a 5 min warm up. The resistance was set at 7.5% bodyweight for the intervals and 2% for the warm up and active recovery periods.
Study NCT00927537 — intervention group
Intervention type: DRUG
Intervention: Telmisartan (Kinzal/Pritor, BAY68-9291)
Description: Patients under daily life treatment receiving Kinzal according to local drug information.
Study NCT02874547 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Intervention
Description: During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
Study NCT02874547 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention
Description: During an in-person visit, patients receive a pamphlet in english and spanish and a storytelling Digital Versatile Disc (DVD) (developed for this project from interviews with hypertensive patients), supplemented by motivational interviewing delivered by the CHW. The CHW explores the patient's motivation to change associated with hypertension and counsels on risk factor control (tobacco, diet, physical activity). Patients receive a followup telephone call from the CHW in 2 weeks, 4 weeks, 2 months to support any changes or goals discussed at first visit. Six months after first intervention visit, patients are invited to schedule an in-person visit with the CHW at the health center to discuss goals and provide support for change.
Study NCT04407663 — intervention group
Intervention type: OTHER
Intervention: Telemedicine to remote outpatient visit in bariatric patient
Description: Patients that referred for the first time to our bariatric center were investigated for anthropometric, psychological and instrumental data in order to evaluate the eligibility for a future bariatric procedure. In established patients, eligibility for tele-consultation was evaluated by three experienced physicians, consulting the stored patients' data. All included patients provided oral informed consent. Patients approached the virtual visit with their personal smart devices, desktop or laptop computer. Medical counselling was performed using a desktop or laptop computer from the Hospital or home in a smart working modality. The video call was carried out using Skype platform by Microsoft®; any document drawn up by the physician was saved as pdf using the Cute Professional™ PDF software, that allows to add passwords and set security options to protect the patients' data.
Study NCT01642797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Confocal laser endomicroscopy (Pentax, EG3870K)
Description: Confocal laser endomicroscopy with Targeted Biopsy
Study NCT01642797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Standard White-light endoscopy (Pentax, 90i)
Description: Standard White-light endoscopy with Standard Biopsy
Study NCT01577394 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oculomotor measurements
Description: The variability is indicated by the coefficient of variation (i.e. standard-error/mean) of saccades latencies in the gap paradigm.~Mean reflexive saccades latency Percentage of express saccades
Study NCT01364064 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: TMZ
Description: Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
Study NCT01364064 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMZ
Description: Comparing conventional adjuvant Temozolomide with dose intensive Temozolomide
Study NCT01215955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin lispro
Description: Administered subcutaneously, up to three times daily for 24 weeks
Study NCT03765437 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Quadrivalent Influenza Vaccine
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study NCT01215955 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine
Description: Administered subcutaneously, dosage determined by investigator once daily for 24 weeks
Study NCT01200381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quarterly remote follow ups and remote monitoring
Description: Quarterly remote follow ups and remote monitoring
Study NCT01200381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quarterly remote follow ups + additional phone calls and remote monitoring
Description: Quarterly remote follow ups + additional phone calls and remote monitoring
Study NCT01200381 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quarterly in clinic follow ups and remote monitoring
Description: Quarterly in clinic follow ups and remote monitoring
Study NCT03765957 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mesenchymal Stem Cells
Description: After the subjects are screened and qualified, random number envelopes will be selected to group 12 subjects into group A, group B, group C and group D at a ratio of 1:1:1:1. The subjetcts of group A and B will be injected intravenously with 1.5x10E6/kg and 2.0x10E6/kg（according to the weight of subject）mesenchymal stem cells respectively at baseline and every 2 weeks, 4 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. The subjetcts of group C and D will be injected intravenously with 2.5x10E6/kg and 3.0x10E6/kg （according to the weight of subject）mesenchymal stem cells respectively at baseline and every 4 weeks, 2 times is a course of treatment. Subjects will be followed up for evaluation on 15 days, 30 days, 45 days, month 2, month 3 and month 6 after treatment. Besides MSCs, moisturizers such as boric acid ointment will be given to all subjects.
Study NCT00972790 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Bilateral Scalp Nerve Blocks
Description: Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
Study NCT00972790 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral Scalp Nerve Blocks
Description: Scalp nerve blocks will be performed bilaterally at the end of the surgery under general anaesthesia and before removal of the head holder. Patients will receive scalp nerve blocks with a total of 20 ml of 0.5% bupivacaine + epinephrine 1:200,000 or 20 ml of saline + epinephrine 1:200,000. Solution volume is as follows: 2ml each bilaterally for supraorbital and supratrochlear nerves; 3 ml for the auriculotemporal nerves; 2 ml for the postauricular branches of the greater auricular nerves and for the greater, lesser, and third occipital nerves 3 ml of solution will be infiltrated along the superior nuchal line, approximately halfway between the occipital protuberance and the mastoid process.
Study NCT03253900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Stable rowing simulator
Description: a standard stable/fixed rowing simulator
Study NCT03253900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Slides based rowing simulator
Description: a slides based rowing simulator, i.e. horizontal plane unstable
Study NCT01230502 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Group 1 Donor Specific Regulation (DSR) +, Mycophenolic acid (MPA) monotherapy
Description: Group 1 Donor Specific Regulation (DSR) +, MPA monotherapy~Mycophenolate sodium : Myfortic therapy will be maintained at a target dose of 720mg BID.~Tacrolimus doses will be lowered to achieve levels of 3-5 ng/ml. 6 months later, immunological monitoring will be repeated and tacrolimus will be completely discontinued if the subject remains DSR + without development of donor specific antibodies (DSA). Those who become DSR- or develop DSA will remain on a tacrolimus dose achieving levels of 3-5 ng/ml, and will not undergone any additional reduction.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples.
Study NCT01230502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: data and sample collection
Description: Group 2 : Donor specific regulation (DSR) + standard of care:~These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment.~Subjects will be followed for 24 months at 6 month intervals, and will provide health information and blood samples
Study NCT01230502 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: data and sample collection
Description: Group 3 : Donor specific regulation (DSR) - standard of care:~These subjects are those who were DSR negative and/or DSA positive at enrollment and therefore are not eligible for the withdrawal aspect of the study. These subjects will be maintained on standard of care immunosuppression consisting of Tacrolimus and Mycophenolate sodium (MPS) with no reduction in tacrolimus dose during the 24 months of study enrollment. These subjects will be asked to provide heath information and donate blood, exclusively for research testing, at the same 6 month intervals as those in the other two arms of the study, and will be followed for 24 months.
Study NCT03253900 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Tilt board based rowing simulator
Description: a tilt board based rowing simulator; i.e. frontal plane unstable
Study NCT03295071 — intervention group
Intervention type: OTHER
Intervention: Patient-reported outcomes (PROs)
Description: Patient-reported outcomes (PROs)
Study NCT02839304 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation System
Description: Pulmonary Vein Isolation, Posterior Wall Isolation. May Include Mitral Line ablation, AF Driver ablation, and Cavo-tricuspid Isthmus ablation as indicated
Study NCT02591277 — intervention group
Intervention type: DRUG
Intervention: Harvoni
Description: Harvoni (90/400 mg) FDC tablet administered orally once daily
Study NCT00765505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Group
Description: Sixteen week intervention where subjects will be progressed to four days per week for 45 minutes per session, 180 minutes minimum per week, of moderate intensity supervised exercise.
Study NCT00765505 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Education Group
Description: Sixteen week intervention. This group will not receive specific exercise education or prescription but will be asked to participate in biweekly health education sessions
Study NCT02198170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketoconazole-placebo
Description: Treatment Period 1: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period. Treatment Period 2: Placebo orally once daily + single oral dose of 5 mg lenvatinib of fifth day on 19-day treatment period.
Study NCT02198170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo-ketoconazole
Description: Treatment Period 1: Placebo orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period Treatment Period 2: 400 mg ketoconazole orally once daily + single oral dose of 5 mg lenvatinib on fifth day of 19-day treatment period
Study NCT02126514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD3293
Description: 7 subjects will receive AZD3293
Study NCT03182933 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peripheral Nerve Blockade
Description: Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
Study NCT03182933 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Peripheral Nerve Blockade
Description: Each study arm will receive their respective formulation of local anesthetic, either standard bupivacaine or liposomal bupivacaine upon randomization
Study NCT02502565 — intervention group
Intervention type: OTHER
Intervention: Uric acid level
Study NCT03534635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab monotherapy at 200 mg every 3 weeks for 2 years maximum.
Study NCT03534635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab - additional treatment
Description: Patients may be retreated for one year of additional pembrolizubmab therapy (200 mg every 3 weeks).
Study NCT00928135 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xylitol
Description: 15% xylitol solution for aerosol; Dosage: 5 ml twice a day (BID)
Study NCT00928135 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hypertonic saline
Description: 7% hypertonic saline solution for aerosol; Dosage: 5 ml twice a day (BID)
Study NCT05354336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390(100mg)
Description: SHR6390 at a single oral dose of 100 mg.
Study NCT05354336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390(125mg)
Description: SHR6390 at a single oral dose of 125 mg.
Study NCT05354336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SHR6390(150mg)
Description: SHR6390 at a single oral dose of 150 mg.
Study NCT03487614 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavior-based parental intervention
Description: Behavioral intervention designed to promote healthy feeding behaviors in parents of 2-5 year olds, and to modify parenting practices in a way that encourages adequate physical activity, sufficient sleep, and healthy nutrition, while limiting sedentary behaviors.
Study NCT02681627 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Endometrial scratch
Description: If patient randomised to intervention arm, will have speculum examination followed by endometrial scratch with a wallace catheter
Study NCT02681627 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Touching the cervix
Description: If patient is randomised to the control arm, she will have speculum examination followed by cleaning of the cervix with a cotton tip dipped in saline
Study NCT02549885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNF contract-relax
Description: Proprioceptive neuromuscular facilitation, using the technique of contract-relax on neck diagonal.
Study NCT02549885 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Static stretching
Description: Static stretching of neck muscles.
Study NCT04379102 — intervention group
Intervention type: OTHER
Intervention: with NT/TLA (NT or also referred to as therapy with local anesthetics (TLA) )
Description: Patients who visited our family planning clinic and opted for IUD application for contraception purposes were also offered NT/TLA treatments simultaneously. 40 patients who matched the inclusion criteria and received IUDs and NT/TLA treatments were included in the study group and 41 patients who only received IUDs were included in the control group. All patients received copper IUDs and none of them were on additional hormonal treatment. Before the insertion of IUD, women in the therapy group received NT treatment with 6ml of 1% procaine injected transvaginal into the cervix at 5 and 7 o'clock localizations.
Study NCT01016431 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rate-adaptive pacemaker programming
Description: The ICD will be programmed in a AAI-R mode, with peak atrial stimulation rate set at 85% of maximal predicted heart rate, and ongoing protection VVI backup at 40 bpm
Study NCT01016431 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VVI at 40 bpm
Description: ICDs will be programmed in VVI mode at 40 bpm
Study NCT01364246 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: human umbilical cord mesenchymal stem cells
Description: Participants will be given hUC-MSCs transplantation.
Study NCT03182933 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: 10 meter walk test on post-operative day 1
Description: Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist
Study NCT03182933 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: 10 meter walk test on post-operative day 1
Description: Patient asked to walk 10 meters at comfortable pace on post-operative day one when deemed safe to do so by the physical therapist
Study NCT03182933 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: In person and over the phone questionnaire
Description: Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores
Study NCT03182933 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In person and over the phone questionnaire
Description: Presuming the patient has left the hospital each patient will be called on post-operative day 2, 3 to assess nausea, opioid consumption, satisfaction with anesthesia technique, nausea and vomiting as well as pain scores
Study NCT03182933 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Force transduction of quadriceps strength
Description: Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1
Study NCT03182933 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Force transduction of quadriceps strength
Description: Patient will be asked to flex quadriceps at maximal ability and a transducer (Kiio device) will record a force value pre operatively and on post operative day 1